KOSDAQRetail & Consumer299170

Wsi

₩1,479▲ 0.75%2026-10-02 close

Market Cap

₩61.2B

Turnover

₩4.3B

Volume

2.9M

Shares out.

41.5M

PER

—

PBR

0.8×

EPS

-₩20

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

From Distribution to Manufacturing and Robotics: Growing Pains

Revenue has grown for four straight years, but operating margin has steadily declined and the company swung to a net loss in 2025, putting the payoff from its new pharma manufacturing and medical robot businesses to the test.

1
Revenue expanded from KRW 27.1bn to KRW 51.7bn between 2022 and 2025, while operating margin fell from 13.6% to 7.6%
2
Owner net income turned to a loss of KRW -3.63bn in 2025, with large quarter-to-quarter swings
3
A research report notes the domestic approval target for the U-BOT surgical assist robot has slipped from H1 2026 to early 2027
4
Subsidiary Introbiopharma's pharmaceutical manufacturing (CDMO) and CRO operations have become a core driver of group revenue growth
5
Management states that financial burden has eased following the extinguishment of convertible bonds

Business structure

WSI grew as a healthcare company built on pharmaceutical and medical device distribution, supplying South Korea's top-selling local hemostatic agent along with spinal surgery endoscopy products, adhesion barriers, and bone hemostatic agents to roughly 400 hospitals and clinics nationwide.

The company laid the foundation of its distribution business by signing a domestic exclusive distribution agreement for Baxter's Floseal hemostatic product in 2018. From 2023, it expanded its portfolio into cardiovascular intervention catheters through partnerships with UK's Kimal and China's Shengjian Tech Group.

In 2024, WSI acquired a 67% stake in pharmaceutical company Introbiopharma and added a further 10% in the first half of 2025, establishing a drug manufacturing and R&D division.

Introbiopharma, which operates a PIC/S GMP-certified facility, has launched an extended-release topiramate anti-epileptic product and a tablet-form bowel cleansing agent, and also acquired CRO subsidiary IBP Lab, which contributes to consolidated results.

Subsidiary Ezmedibot has developed U-BOT, a uterine positioning robot that assists laparoscopic gynecological surgery, with a planned revenue structure combining device sales and disposable consumables branded Utru GyneX.

The company plans to expand its medical robot lineup beyond U-BOT to include a brain-surgery robot (B-BOT), a skull-base robot (E-BOT), and a cardiovascular robot (C-BOT).

Management has stated a goal of shifting the business mix from distribution toward manufacturing and development, targeting KRW 100bn in consolidated revenue by 2028.

Earnings trend

Quarterly revenue · Operating profit

₩13B₩1.1B25Q2₩13.4B₩1.1B25Q3₩12.5B₩600M25Q4₩11.9B-₩200M26Q1₩12.9B₩1B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩27.1B₩3.7B2022₩30.9B₩3.3B2023₩40.4B₩3.9B2024₩51.7B₩3.9B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩13B	₩1.1B	8.6%
2025Q3	₩13.4B	₩1.1B	8.5%
2025Q4	₩12.5B	₩600M	4.9%
2026Q1	₩11.9B	-₩200M	−1.4%
2026Q2	₩12.9B	₩1B	7.9%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩27.1B	₩3.7B	₩4.3B	13.6%	11.4%	50.9%
2023	₩30.9B	₩3.3B	₩2.8B	10.8%	7.0%	50.1%
2024	₩40.4B	₩3.9B	₩1.3B	9.5%	3.2%	86.7%
2025	₩51.7B	₩3.9B	-₩3.6B	7.6%	−6.1%	38.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

Earnings analysis

Consolidated revenue grew for four straight years, from KRW 27.1bn in 2022 to KRW 30.9bn in 2023, KRW 40.4bn in 2024, and KRW 51.7bn in 2025.

In contrast, operating margin declined steadily from 13.6% in 2022 to 10.8% in 2023, 9.5% in 2024, and 7.6% in 2025, reflecting rising manufacturing, R&D, and SG&A costs tied to the consolidation of Introbiopharma.

Owner net income fell from KRW 4.31bn in 2022 to KRW 2.83bn in 2023 and KRW 1.32bn in 2024, before swinging to a loss of KRW -3.63bn in 2025.

On a quarterly basis, both Q2 2025 (operating profit KRW 1.11bn, owner net loss KRW -2.52bn) and Q4 2025 (operating profit KRW 0.61bn, owner net loss KRW -2.68bn) posted positive operating profit alongside sizeable net losses, suggesting non-operating items had a material impact on bottom-line results.

Q3 2025 returned to overall profitability with revenue of KRW 13.42bn, operating profit of KRW 1.14bn, and owner net income of KRW 0.96bn.

Q1 2026 saw revenue of KRW 11.95bn and an operating loss of KRW 0.17bn, marking the quarter's first operating loss in this window, though owner net income stayed slightly positive at KRW 0.10bn, before Q2 2026 improved again to revenue of KRW 12.93bn, operating profit of KRW 1.03bn, and owner net income of KRW 0.85bn.

Management has said financial burden eased following the extinguishment of convertible bonds, which may partly explain some of the past quarterly net income volatility.

Over the most recent four-quarter window from Q3 2025 through Q2 2026, cumulative operating profit remained positive while owner net income was slightly negative, indicating that earnings quality has yet to fully catch up with top-line growth.

Industry analysis

South Korea's medical device and pharmaceutical distribution industry is characterized by a stable revenue base anchored in hospital and clinic networks, but distributors facing growth limits are increasingly diversifying into manufacturing and development.

WSI has been cited as an early mover in this shift, having acquired robotics firm Ezmedibot in 2022 and pharmaceutical manufacturer Introbiopharma in 2024.

The global surgical robotics market is projected to grow from about USD 8.28bn in 2025 to about USD 16.4bn by 2032, meaning the market that U-BOT and its planned successors aim to enter is itself expanding.

However, the surgical robot market remains dominated by the global leader behind the da Vinci system, and analysts have positioned U-BOT as a complementary device that can be used alongside such systems rather than compete with them directly.

The cardiovascular intervention device market, anchored by exclusive supply agreements with UK's Kimal and China's Shengjian Tech Group, is viewed as a higher-growth segment, though competition from larger domestic distributors and global manufacturers persists.

In pharmaceutical manufacturing (CDMO), Introbiopharma's PIC/S GMP-certified facility has secured new revenue streams through generic drug products such as an anti-epileptic and a bowel cleansing agent, though the domestic anti-epileptic and bowel-cleansing markets are each estimated at only about KRW 80bn and KRW 50bn, limiting the absolute size of the opportunity.

Outlook

Subsidiary Ezmedibot was successively selected in 2026 for the Ministry of Food and Drug Safety-affiliated Korea Medical Device Safety Information Institute's innovative medical device support program and for market-entry and licensing consulting programs run by the Korea Health Industry Development Institute, both intended to support U-BOT's regulatory approval process.

Independent research firm GL Research noted in a June 2026 report that U-BOT is targeting completion of a final mass-production prototype within the third quarter and MFDS approval by early 2027, a timeline later than the "launch by end of H1 2026" scenario cited in a KB Securities report from November 2025.

U-BOT is pursuing patent registration in the United States and across 19 European countries, with plans to sequentially pursue European CE certification and US FDA approval following domestic approval.

The robot lineup is planned to expand beyond U-BOT to a brain-surgery robot, a skull-base robot, and a cardiovascular robot, and in April the subsidiary signed a strategic partnership with Beijing HTKD Medical in China.

Subsidiary Introbiopharma is pursuing development of an oral GLP-1 obesity treatment based on its proprietary Imulpass platform as a next growth driver, currently conducting preclinical testing while preparing patent filings.

Management has stated its policy for 2026 is to build on revenue diversification achieved so far and pursue balanced growth across its healthcare and medical robotics segments along with tangible profit improvement.

Valuation

PER

—

PBR

0.8×

ROE

-1.5%

EPS

-₩20

BPS

₩1,476

Dividend per share

₩0

With owner net income having turned to a loss in 2025, applying a traditional price-to-earnings valuation framework is difficult in the current period. The price-to-book ratio sits below 1x, meaning shares trade at a discount to net asset value.

While revenue has grown steadily over multiple years, profitability shifted from positive to negative and has continued to swing quarter to quarter, so any future valuation discussion is likely to hinge on the pace of commercialization in the robotics and pharmaceutical businesses and whether profitability recovers.

The company currently pays no dividend, making dividend-based valuation metrics inapplicable. Brokerage reports reviewed have generally refrained from setting target prices, instead focusing on qualitative analysis of the growth potential in the robotics and pharmaceutical segments.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

Bull factors

Medical Robot Lineup Expansion and Overseas IP Protection

Ezmedibot plans to expand its robot lineup starting with U-BOT and extending to B-BOT, E-BOT, and C-BOT, while pursuing patent registration in the United States and across 19 European countries.

U-BOT is designed around a revenue structure combining device hardware with disposable Utru GyneX consumables, which could become a recurring revenue source once commercialized.

In 2026 the subsidiary was also selected for consecutive regulatory support programs run by agencies under the Ministry of Food and Drug Safety, adding an institutional support layer.

Successful Diversification into Pharmaceutical Manufacturing (CDMO)

Introbiopharma has launched new products such as an anti-epileptic and a bowel cleansing agent based on its PIC/S GMP-certified facility, establishing itself as a core driver of group revenue growth. The acquisition of CRO subsidiary IBP Lab has extended the business into contract clinical research services.

The pursuit of an oral GLP-1 obesity treatment as a new growth driver means the pharmaceutical segment's revenue contribution and diversity continue to expand.

Eased Financial Burden and Cardiovascular Business Diversification

Management has stated that financial burden eased following the extinguishment of convertible bonds, with the debt ratio falling from 86.7% in 2024 to 38.6% in 2025.

The cardiovascular intervention business, built on exclusive supply agreements with UK's Kimal and China's Shengjian Tech Group, is cited as a higher-margin growth driver that reduces reliance on the single hemostatic-agent product line. This revenue diversification strategy has been credited with translating into actual top-line growth.

Bear factors

Operating Margin Decline Despite Revenue Growth

Operating margin has fallen for four consecutive years, from 13.6% in 2022 to 7.6% in 2025. While revenue grew from KRW 27.1bn to KRW 51.7bn, rising R&D and SG&A costs tied to new businesses have continued to pressure margins.

Top-line growth has not translated into improved profitability, indicating that the cost structure of the new businesses has yet to stabilize.

Repeated Delays in U-BOT's Approval Timeline

A KB Securities report from November 2025 cited a target launch of "end of H1 2026" for U-BOT, but a GL Research report from June 2026 pushed the target to MFDS approval by early 2027. This suggests the actual commercialization timeline has continued to slip relative to initial expectations.

Factoring in the planned CE and FDA approvals that would follow domestic approval, any contribution from overseas sales could be pushed out further.

Earnings Volatility and Reduced Predictability

In both Q2 and Q4 of 2025, operating profit was positive yet owner net income posted large losses of KRW -2.52bn and KRW -2.68bn, respectively. Conversely, Q1 2026 recorded an operating loss while net income stayed slightly positive, reflecting a recurring gap between operating performance and bottom-line results. This pattern can make it more difficult to gauge future earnings trends with confidence.

Risk factors

Regulatory and Approval Risk

The target timeline for U-BOT's MFDS product approval has already slipped at least once, and further delays cannot be ruled out. A KB Securities report explicitly cited approval delays and drug pricing regulation as key risk factors.

Additional time and cost may also be required during the subsequent European CE and US FDA certification processes.

Earnings Volatility Risk

Owner net income turned to a loss for full-year 2025, and quarterly results repeatedly showed operating profit and net income moving in opposite directions. If volatility driven by non-operating factors persists, concerns over earnings quality could continue. Cost burdens such as R&D spending may also persist as investment in new businesses (robotics, GLP-1) continues.

Competition and Execution Risk

The surgical robot market remains dominated by the global leader behind the da Vinci system, meaning U-BOT may need time to establish itself commercially. The oral GLP-1 obesity treatment market is an intensely competitive field contested by large global pharmaceutical companies.

As a smaller healthcare company pursuing multiple new initiatives simultaneously—robot lineup expansion, pharmaceutical CDMO, and GLP-1 development—resource allocation and execution capability could become key determinants of success.

What to watch next

During Q3 2026
This is the target period GL Research cited for completion of U-BOT's final mass-production prototype; actual progress should be verified through disclosures and IR materials.
Around November 2026 (expected Q3 2026 earnings disclosure)
This will be a point to check whether the earnings volatility seen in Q1-Q2 2026 is stabilizing, based on Q3 2026 revenue and operating profit trends.
During H2 2026
Progress on Introbiopharma's GLP-1-related patent filings, preclinical testing, and preparations to begin clinical trials should be monitored.
Early 2027
This is the MFDS approval target for U-BOT cited by GL Research; whether actual approval is obtained and whether subsequent CE/FDA certification processes begin should be checked.

Overall view

WSI is in a transitional phase, building two new business pillars—pharmaceutical manufacturing (Introbiopharma) and medical robotics (Ezmedibot)—on top of its stable pharmaceutical and medical device distribution base.

Revenue grew steadily from 2022 through 2025, but operating margin declined continuously, and owner net income turned to a loss in 2025, widening the gap between top-line growth and profitability.

Quarterly results show a recurring pattern in which operating profit and final net income move in opposite directions, leaving improved earnings predictability as an ongoing challenge.

The company's key growth driver, the U-BOT surgical assist robot, has seen its domestic approval target slip from H1 2026 to early 2027 according to a recent research report, warranting close monitoring of actual commercialization progress.

The pharmaceutical segment's progress is comparatively more concrete, with new product launches and the consolidation of a CRO subsidiary already contributing visibly to revenue.

The easing of financial burden following the extinguishment of convertible bonds is a positive development, but earnings quality and volatility will need to be watched closely as investment in new businesses continues.

This report provides no investment opinion or buy/sell recommendation and is intended for informational purposes only.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.